1. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
- Author
-
Gilles Montalescot, Arnoud W. van ’t Hof, Leonardo Bolognese, Warren J. Cantor, Angel Cequier, Mohamed Chettibi, Jean-Philippe Collet, Shaun G. Goodman, Christopher J. Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Muriel Licour, Béla Merkely, Néjoua Salhi, Johanne Silvain, Robert F. Storey, Jurriën M. ten Berg, Anne Tsatsaris, Uwe Zeymer, Eric Vicaut, Christian W. Hamm, Rachid Bougherbal, Mohamed Tahar Bouafia, Djamaleddine Nibouche, Abdelkader Moklati, Ahmed Benalia, Omar Kaid, Messaad Krim, Christopher Hammett, Paul Garrahy, Rohan Jayasinghe, Stephen Rashford, Thomas Neunteufl, Helmut Brussee, Hannes Alber, Franz Weidinger, Michael Brunner, Johann Sipoetz, Gerhard Prause, Michael Baubin, Dieter Sebald, Warren Cantor, Ram Vijayaraghavan, Iqbal Bata, Andrea Lavoie, Jan Ravkilde, Lisette Okkels Jensen, Alf Møl Christensen, Marianne Toftegaard, Dennis Köhler, Gregory Ducrocq, Nicolas Danchin, Patrick Henry, Bernard Livarek, Romain Berthier, Thomas Hovasse, Philippe Garot, Laurent Payot, Hakim Benamer, Jean Baptiste Esteve, Simon Elhadad, Emmanuel Teiger, Jean Louis Bonnet, Franck Paganelli, Yves Cottin, François Schiele, Christophe Thuaire, Guillaume Cayla, Pierre Coste, Patrick Ohlmann, Eric Bonnefoy Cudraz, Pierre Lantelme, Thibault Perret, Christophe Tron, Axel De Labriolle, Edouardo Aptecar, Olivier Beliard, Olivier Varenne, Rami El Mahmoud, Emmanuelle Filippi-Codaccioni, Denis Angoulvant, Patrick Peycher, Olivier Poitrineau, Xavier Tabone, Patrick Ecollan, Claire Broche, Yves Lambert, Nicolas Briole, Arielle Beruben, Nicolas Porcher, Jean-Pierre Auffray, Marc Freysz, Franck Depardieu, David Poubel, Jean-Emmanuel De La Cousaye, Jean-Claude Bartier, Benoît Jardel, Bertrand Boulanger, Hervé Labourel, Louis-Christophe Soulat, Véronique Julie, Michel Thicoipe, Olivier Capel, Olivier Stibbe, Pierre Carli, Karim Tazarourte, Fabrice Alcouffe, David Aboucaya, Gaële Aubert, Gérald Kierzek, Séverine Cahun-Giraud, Christian Hamm, Thomas Dengler, Roland Prondzinsky, Paul Marc Biever, Andreas Schäfer, Melchior Seyfarth, Bernd Lemke, Gerald Werner, Holger Nef, Holger Steiger, Matthias Leschke, Thomas Münzel, Marco Campo Dell Orto, Christian Loges, Monika Schinke, Frank Koberne, Hans Peter Reiffen, Klaus Tiroch, Dirk Wierich, Michael Kneussel, Simon Little, Hartmut Sauer, Rita Laufenberg-Feldmann, Imre Ungi, Iván Horváth, István Édes, István Mártai, Sergio Berti, Francesco Chiarella, Paolo Calabria, Massimo Fineschi, Marcello Galvani, Marco Valgimigli, Luciano Moretti, Maurizio Tespili, Massimo Mandó, Francesco Bermano, Robusto Biagioni, Andrea Fabbri, Adelina Ricciardelli, Maria Romana Petroni, Umberto Roberto Vatteroni, Francesco Palumbo, Frank F. Willems, Amar Al Mafragi, Ton A.A.C.M. Heestermans, Martijn J. Van Eck, Wim M.J.M. Heutz, H.H. Meppelder, Anika Roukema-de Jong, Harm Van de Pas, Ángel Cequier Fillat, Manel Sabaté Tenas, Josepa Mauri Ferrer, Antoni Serra Peñaranda, Joan Ángel Ferrer, Bruno García Del Blanco, Faustino Miranda Guardiola, Juan Miguel Ruiz Nodar, Andrés Íñiguez Romo, Nicolás Vázquez González, Ramiro Trillo Nouche, Luis Díaz De La Llera, José María Hernández García, Fernando Rivero-Crespo, Felipe Hernández Hernández, José Luis Zamorano Gómez, Xavier Jiménez Fárega, Gilberto Alonso Fernández, José Luis Toboso, Mercedes Carrasco, Victoria Barreiro, José Antonio Iglesias Vázquez, María del Mar Ruiz Montero, Fernando Rosell Ortiz, Guillermo Garcia Escudero, Vicente Sánchez-Brunete Ingelmo, Antonio Lara García, Jonas Oldgren, Fredrik Calais, Robert Kastberg, Per-Adolf Bergsten, Hans Blomberg, Kristian Thörn, Gunnar Skoog, Azfar Zaman, Robert Gerber, Alisdair Ryding, Mark Spence, Neil Swanson, Martin Been, Konrad Grosser, Peter Schofield, David Mackin, Paul Fell, Tom Quinn, Teresa Foster, David McManus, Andy Carson, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AstraZeneca, Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Hôpital avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7)
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Coronary thrombosis ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,medicine ,ST segment ,030212 general & internal medicine ,Myocardial infarction ,thrombosis ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,3. Good health ,reperfusion ,myocardial infarction ,stents ,Conventional PCI ,platelets ,Cardiology ,Platelet aggregation inhibitor ,Cardiology and Cardiovascular Medicine ,business ,Ticagrelor ,TIMI ,medicine.drug - Abstract
Objectives The aim of this landmark exploratory analysis, ATLANTIC-H 24 , was to evaluate the effects of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention (PCI) in the ATLANTIC (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery) study. Background The ATLANTIC trial in patients with ongoing ST-segment elevation myocardial infarction showed that pre-hospital ticagrelor was safe but did not improve pre-PCI coronary reperfusion compared with in-hospital ticagrelor. We hypothesized that the effect of pre-hospital ticagrelor may not have manifested until after PCI due to the rapid transfer time (31 min). Methods The ATLANTIC-H 24 analysis included 1,629 patients who underwent PCI, evaluating platelet reactivity, Thrombolysis In Myocardial Infarction flow grade 3, ≥70% ST-segment elevation resolution, and clinical endpoints over the first 24 h. Results Following PCI, largest between-group differences in platelet reactivity occurred at 1 to 6 h; coronary reperfusion rates numerically favored pre-hospital ticagrelor, and the degree of ST-segment elevation resolution was significantly greater in the pre-hospital group (median, 75.0% vs. 71.4%; p = 0.049). At 24 h, the composite ischemic endpoint was lower with pre-hospital ticagrelor (10.4% vs. 13.7%; p = 0.039), as were individual endpoints of definite stent thrombosis (p = 0.0078) and myocardial infarction (p = 0.031). All endpoints except death (1.1% vs. 0.2%; p = 0.048) favored pre-hospital ticagrelor, with no differences in bleeding events. Conclusions The effects of pre-hospital ticagrelor became apparent after PCI, with numerical differences in platelet reactivity and immediate post-PCI reperfusion, associated with reductions in ischemic endpoints, over the first 24 h, whereas there was a small excess of mortality. (Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery [ATLANTIC, NCT01347580 ])
- Published
- 2016
- Full Text
- View/download PDF